Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Baricitinib Versus Azathioprine in Combination With Topical Corticosteroids For Patients With Moderate-to-Severe Atopic Dermatitis

Next Previous
Trial Profile

Efficacy and Safety of Baricitinib Versus Azathioprine in Combination With Topical Corticosteroids For Patients With Moderate-to-Severe Atopic Dermatitis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Fluocinolone acetonide (Primary) ; Urea (Primary) ; Azathioprine
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Acronyms BAAZ-AD-IR

Most Recent Events

  • 06 May 2025 Status changed from recruiting to active, no longer recruiting.
  • 17 May 2024 Planned End Date changed from 15 Aug 2024 to 30 Jun 2025.
  • 17 May 2024 Planned primary completion date changed from 15 Aug 2024 to 30 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top